Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging
Brain serotonin 6 receptor (5-HT6) is one of the most recently identified serotonin receptors. It is a potent therapeutic target for psychiatric and neurological diseases, e.g. schizophrenia and Alzheimer’s disease. Since no specific fluorinated radioligand has yet been successfully used to study this receptor by positron emission tomography (PET) neuroimaging, the objective of the present study was to study the first 5-HT6 18F-labelled radiotracer.
2FNQ1P, inspired by the quinolone core of a previous radiotracer candidate, GSK215083, was selected according its 5-HT6 affinity and selectivity and was radiolabelled by 18F nucleophilic substitution. The cerebral distribution of [18F]2FNQ1P was studied in vivo in rats, cats and macaque monkeys.
The chemical and radiochemical purities of [18F]2FNQ1P were >98 %. In rats, in vitro competition with the 5-HT6 antagonist, SB258585, revealed that the radioligand was displaced dose dependently. Rat microPET studies showed low brain uptake of [18F]2FNQ1P, reversed by the P-glycoprotein inhibitor, cyclosporin. On the contrary, PET scans in cats showed good brain penetration and specific striatal binding blocked after pretreatment with unlabelled 2FNQ1P. PET scans in macaque monkeys confirmed high specific binding in both cortical and subcortical regions, specifically decreased by pretreatment with the 5-HT6 receptor antagonist, SB258585.
2FNQ1P was initially selected because of its suitable characteristics for 5-HT6 receptor probing in vitro in terms of affinity and specificity. Although in vivo imaging in rats cannot be considered as predictive of the clinical characteristics of the radiotracer, [18F]2FNQ1P appeared to be a suitable 5-HT6 PET tracer in feline and primate models. These preclinical results encourage us to pursue the clinical development of this first fluorinated 5-HT6 PET radiotracer.
KeywordsPET Tracer development Serotonin Rat Cat Monkey
The authors are grateful to Sylvain Fieux for his contribution in animal procedures. Valuable help was provided by Didier Le Bars (CERMEP-Université Claude Bernard Lyon 1) and Guillaume Villeret (ORA Company) in radiochemistry.
Conflicts of interest
- 20.Ahmed M, Jones MC, MacDonald GJ, Moss SF, Thompson M, Wade CE, Witty D. Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders. Patent Application Publication WO2003080580A2 2003.Google Scholar
- 21.Martarello L, Ahmed M, Chuang AT, Cunnigham VJ, Jakobsen S, Johnson CN, et al. Radiolabelling and in vivo evaluation of [11C]GSK210583 as a potential 5-HT6 PET radioligand in the porcine brain. J Labelled Comp Radiopharm 2005;48:341.Google Scholar
- 25.Liu F, Majo VJ, Prabhakaran J, Milak MS, John Mann J, Parsey RV, et al. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors. Bioorg Med Chem 2011;19:5255–9.CrossRefPubMedGoogle Scholar
- 26.Zhang LV A, Anderson D, Beck E, Blumberg L, Bocan T, Bronk B, et al. Development of design and selection parameters to accelerate the discovery process of novel CNS PET ligands and their application in the identification of a potential 5HT6 PET ligand [11C]PF-1. J Labelled Comp Radiopharm 2011;54:S292.CrossRefGoogle Scholar
- 27.Black LA. Radiolabeled 5-HT6 ligands. Patent Application Publication US 2013/0343993A1.Google Scholar
- 29.Snyder WT. A stereotaxic atlas of the cat brain. Chicago: University of Chicago Press; 1961.Google Scholar
- 37.Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003;64:1295–308.CrossRefPubMedGoogle Scholar